Join

Compare · MRK vs VHAQ

MRK vs VHAQ

Side-by-side comparison of Merck & Company Inc. (MRK) and Viveon Health Acquisition Corp. (VHAQ): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MRK and VHAQ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • MRK is the larger of the two at $276.54B, about 1093.8x VHAQ ($252.8M).
  • MRK has hit the wire 9 times in the past 4 weeks while VHAQ has been quiet.
  • MRK has more recent analyst coverage (25 ratings vs 0 for VHAQ).
MetricMRKVHAQ
Company
Merck & Company Inc.
Viveon Health Acquisition Corp.
Price
$111.84-2.43%
$11.30+0.00%
Market cap
$276.54B
$252.8M
1M return
-6.32%
-
1Y return
+34.42%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
AMEX
IPO
2021
News (4w)
9
0
Recent ratings
25
0
MRK

Merck & Company Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

VHAQ

Viveon Health Acquisition Corp.

Viveon Health Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Norcross, Georgia.

Latest MRK

Latest VHAQ